Showing results (51-60 of 610) with videos related to

Sort By:
Pageof 61
Future Oncology (London, England)|November 13, 2025
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E-mutant metastatic colorectal cancerScott Kopetz, Josep Tabernero, Elena Élez
Cancer Journal (Sudbury, Mass.)|June 8, 2010
Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapyCésar Serrano, Ben Markman, Josep Tabernero
Therapeutic Advances in Medical Oncology|May 31, 2016
Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapyHelena Verdaguer, Josep Tabernero, Teresa Macarulla
Expert Opinion on Emerging Drugs|November 24, 2021
Emerging biological drugs for the treatment of gastroesophageal adenocarcinomaMaria Alsina, Marc Diez, Josep Tabernero
Cancers|March 25, 2022
Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and BeyondMaria Alsina, Josep Tabernero, Marc Diez
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Personalizing Adjuvant Therapy for Stage II/III Colorectal CancerNadine Jackson McCleary, Al B Benson, Rodrigo Dienstmann
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2011
Micromanaging the classification of colon cancer: the role of the microRNAomeEduardo Vilar, Josep Tabernero, Stephen B Gruber
Molecular Cancer Therapeutics|January 11, 2011
Pushing the envelope in the mTOR pathway: the second generation of inhibitorsEduardo Vilar, Jose Perez-Garcia, Josep Tabernero
Recent Patents on Anti-Cancer Drug Discovery|June 10, 2008
Aurora kinase family: a new target for anticancer drugTeresa Macarulla, Francisco Javier Ramos, Josep Tabernero
Pageof 61